HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Enis Novalija Selected Research

sevoflurane (Ultane)

8/2003Reactive oxygen species precede the epsilon isoform of protein kinase C in the anesthetic preconditioning signaling cascade.
8/2003Anesthetic preconditioning: effects on latency to ischemic injury in isolated hearts.
5/2003Anesthetic preconditioning improves adenosine triphosphate synthesis and reduces reactive oxygen species formation in mitochondria after ischemia by a redox dependent mechanism.
4/2003Sevoflurane exposure generates superoxide but leads to decreased superoxide during ischemia and reperfusion in isolated hearts.
2/2003Preconditioning with sevoflurane reduces changes in nicotinamide adenine dinucleotide during ischemia-reperfusion in isolated hearts: reversal by 5-hydroxydecanoic acid.
12/2002Anesthetic preconditioning attenuates mitochondrial Ca2+ overload during ischemia in Guinea pig intact hearts: reversal by 5-hydroxydecanoic acid.
10/2002Sevoflurane preconditioning before moderate hypothermic ischemia protects against cytosolic [Ca(2+)] loading and myocardial damage in part via mitochondrial K(ATP) channels.
7/2002Altered NADH and improved function by anesthetic and ischemic preconditioning in guinea pig intact hearts.
7/2002Anesthetic preconditioning: triggering role of reactive oxygen and nitrogen species in isolated hearts.
1/2002Sevoflurane before or after ischemia improves contractile and metabolic function while reducing myoplasmic Ca(2+) loading in intact hearts.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Enis Novalija Research Topics

Disease

17Ischemia
04/2008 - 01/2002
7Reperfusion Injury
10/2007 - 01/2002
2Ventricular Fibrillation
04/2008 - 01/2002
2Hypothermia
04/2004 - 06/2002
1Necrosis
10/2007
1Infarction
02/2003

Drug/Important Bio-Agent (IBA)

10sevoflurane (Ultane)FDA LinkGeneric
08/2003 - 01/2002
4Reactive Oxygen Species (Oxygen Radicals)IBA
11/2005 - 04/2003
4Adenosine Triphosphate (ATP)IBA
05/2003 - 06/2002
45-hydroxydecanoic acidIBA
04/2003 - 10/2002
3Anesthetics (Anesthetic Agents)IBA
08/2003 - 01/2002
3manganese(III)-tetrakis(4-benzoic acid)porphyrinIBA
05/2003 - 02/2003
2crystalloid solutionsIBA
11/2003 - 01/2002
2NAD (NADH)IBA
02/2003 - 07/2002
1IsofluraneFDA LinkGeneric
04/2008
1salicylhydroxamic acid (SHAM)IBA
04/2008
1S-NitrosothiolsIBA
10/2007
1S-nitrosocysteineIBA
10/2007
1triphenyltetrazoliumIBA
10/2007
1Oxidants (Oxidizing Agents)IBA
11/2003
1dityrosineIBA
11/2003
1Nitric Oxide (Nitrogen Monoxide)FDA Link
11/2003
1Dopamine (Intropin)FDA LinkGeneric
10/2003
1DobutamineFDA LinkGeneric
10/2003
1simendan (Levosimendan)IBA
10/2003
1Digoxin (Digitek)FDA LinkGeneric
10/2003
1Cardiotonic Agents (Cardiac Stimulants)IBA
10/2003
1Opioid Analgesics (Opioids)IBA
08/2003
1chelerythrineIBA
08/2003
1Protein Kinase C-epsilonIBA
08/2003
1Superoxide DismutaseIBA
05/2003
11,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium SaltIBA
05/2003
1PotassiumIBA
04/2003
1Superoxides (Superoxide)IBA
04/2003
1ManganeseIBA
04/2003
1dimemorfan (AT 17)IBA
10/2002
1mitochondrial K(ATP) channelIBA
10/2002
1NG-Nitroarginine Methyl Ester (L-NAME)IBA
07/2002
1OxygenIBA
01/2002

Therapy/Procedure

1Aftercare (After-Treatment)
10/2007
1Induced Heart Arrest (Cardioplegia)
05/2003